GSK phase III study supports safety & efficacy of Shingrix in preventing shingles in auHSCT patients

GlaxoSmithKline has announced that new data from a phase III clinical study supports the safety and efficacy of Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in preventing shingles (herpes zoster) when given to adults 18 years and above shortly after undergoing autologous haematopoietic stem cell transplant (auHSCT). GSK phase III study supports safety & efficacy of Shingrix in preventing shingles in auHSCT patients. This is the first time that Shingrix efficacy has been evaluated in immune-compromised patients such as those who have received auHSCT and who are at higher risk of developing shingles and its complications. ZOE-HSCT was a phase III clinical study to evaluate the efficacy, safety and immunogenicity of a two-dose course of Shingrix for prevention of shingles (herpes zoster) when given to adults 18 years and above with the first dose administered 50-70 days after they had undergone autologous haematopoietic stem cell transplant (auHSCT).

First found on: www.pharmabiz.com